Prevention of acute respiratory problems in children

Preventive effect of pentoxifylline in Acute Respiratory Distress Syndrome susceptible children

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190522043672N2

Enrollment

Registered

2020-10-07

Start date

2020-09-05

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome. Acute respiratory distress syndrome

Interventions

Intervention 1: Intervention group: The suspension prepared from pentoxifylline tablets, which is administered immediately, is given orally at a dose of 20 mg / kg / day in three divided doses for one

Eligibility

Sex/Gender

All

Age

1 Months to 18 Years

Inclusion criteria

Inclusion criteria: All patients at risk for ARDS who have lips=4 based on lung injury prediction score (lips) and do not complete the ARDS diagnosis criteria

Exclusion criteria

Exclusion criteria: Acute prenatal hypoxemia such as premature infant-related lung disease, prenatal lung injury (such as Meconium Aspiration Syndrome, pneumonia, and sepsis occurring during childbirth) are excluded. A disease that inevitably leads to death and is contrary to life Children with adrenal insufficiency Inflammation of blood vessels Patients with intolerance to methylxanthine and pentoxifylline

Design outcomes

Primary

Measure	Time frame
Incidence of acute respiratory distress syndrome. Timepoint: During the study and at the end of the study. Method of measurement: Diagnosis based on criteria for diagnosing acute respiratory distress syndrome.;Heart rate. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.;Respiration rate. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.;Continuous pulse oximetry. Timepoint: At baseline and during the receive of the medication. Method of measurement: Capnography.;Blood gas factors. Timepoint: At baseline and during the receive of the medication. Method of measurement: Capnography.;Blood pressure. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.	—

Measure

Time frame

Incidence of acute respiratory distress syndrome. Timepoint: During the study and at the end of the study. Method of measurement: Diagnosis based on criteria for diagnosing acute respiratory distress syndrome.;Heart rate. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.;Respiration rate. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.;Continuous pulse oximetry. Timepoint: At baseline and during the receive of the medication. Method of measurement: Capnography.;Blood gas factors. Timepoint: At baseline and during the receive of the medication. Method of measurement: Capnography.;Blood pressure. Timepoint: At baseline and during the receive of the medication. Method of measurement: Cardiac Monitoring.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Houshang Mohammadpour

Mashhad University of Medical Sciences

mohamadpoorah@mums.ac.ir+98 51 3180 1100

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026